Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
BUSINESS
Nippon Kayaku Notches Top Court Victory for Elplat Damages Suit Too
Nippon Kayaku said on March 29 that Japan’s Supreme Court found in favor of the generic maker in a damages suit over its generic versions of Elplat (oxaliplatin) brought on by Swiss-based Debiopharm International SA and Yakult Honsha, the developer…
To read the full story
Related Article
- Nippon Kayaku Clinches Supreme Court Victory in Elplat Patent Suit
October 6, 2017
- Nippon Kayaku Prevails in Elplat Damage Suit: High Court
June 30, 2017
- Debiopharm Takes Nippon Kayaku to Supreme Court over Elplat
February 22, 2017
- Nippon Kayaku Wins Reversal in Elplat Patent Suit
December 9, 2016
- Nippon Kayaku Faces Damage Suit over Elplat Patent
May 17, 2016
- Debiopharm Wins Elplat Patent Suit against Nippon Kayaku
March 8, 2016
BUSINESS
- Expert Calls for Greater Awareness of LC-FAOD after Dojolvi Debut
June 30, 2026
- Toho Defense Measure Scraped through Shareholder Vote: Report
June 30, 2026
- Enhertu Snags EU Approval in HER2 Positive Solid Tumors
June 30, 2026
- Datroway Grabs Positive CHMP Opinion in 1st-Line TNBC
June 30, 2026
- Tanabe Gets Thai Approval for Diabetes Drug Canalia
June 30, 2026
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s leading pharmaceutical wholesalers are bracing for a second consecutive year of profit declines, underscoring the growing challenge of generating…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…